- Home
- RNTX vs FLNT Comparison
RNTX vs FLNT Comparison
Compare RNTX & FLNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- FLNT
- Stock Information
- Founded
- RNTX 2001
- FLNT 2001
- Country
- RNTX United States
- FLNT United States
- Employees
- RNTX N/A
- FLNT N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- FLNT Advertising
- Sector
- RNTX Health Care
- FLNT Consumer Discretionary
- Exchange
- RNTX Nasdaq
- FLNT Nasdaq
- Market Cap
- RNTX 40.3M
- FLNT 39.2M
- IPO Year
- RNTX N/A
- FLNT N/A
- Fundamental
- Price
- RNTX $1.45
- FLNT $2.12
- Analyst Decision
- RNTX
- FLNT Hold
- Analyst Count
- RNTX 0
- FLNT 1
- Target Price
- RNTX N/A
- FLNT $3.00
- AVG Volume (30 Days)
- RNTX 37.4K
- FLNT 10.7K
- Earning Date
- RNTX 08-13-2025
- FLNT 08-18-2025
- Dividend Yield
- RNTX N/A
- FLNT N/A
- EPS Growth
- RNTX N/A
- FLNT N/A
- EPS
- RNTX N/A
- FLNT N/A
- Revenue
- RNTX N/A
- FLNT $243,850,000.00
- Revenue This Year
- RNTX N/A
- FLNT N/A
- Revenue Next Year
- RNTX N/A
- FLNT $11.62
- P/E Ratio
- RNTX N/A
- FLNT N/A
- Revenue Growth
- RNTX N/A
- FLNT N/A
- 52 Week Low
- RNTX $1.33
- FLNT $1.50
- 52 Week High
- RNTX $4.40
- FLNT $3.83
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- FLNT 65.17
- Support Level
- RNTX N/A
- FLNT $1.93
- Resistance Level
- RNTX N/A
- FLNT $2.10
- Average True Range (ATR)
- RNTX 0.00
- FLNT 0.14
- MACD
- RNTX 0.00
- FLNT 0.04
- Stochastic Oscillator
- RNTX 0.00
- FLNT 96.15
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.